Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to 61.84%.

  • Ironwood Pharmaceuticals' EBIT Margin rose 338500.0% to 61.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 36.34%, marking a year-over-year increase of 101200.0%. This contributed to the annual value of 26.5% for FY2024, which is 2400400.0% up from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' EBIT Margin is 61.84%, which was up 338500.0% from 53.17% recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' EBIT Margin peaked at 63.77% during Q4 2022, and registered a low of 1008.68% during Q2 2023.
  • For the 5-year period, Ironwood Pharmaceuticals' EBIT Margin averaged around 14.07%, with its median value being 51.1% (2021).
  • In the last 5 years, Ironwood Pharmaceuticals' EBIT Margin crashed by -10659200bps in 2023 and then skyrocketed by 10351400bps in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' EBIT Margin (Quarter) stood at 48.32% in 2021, then surged by 32bps to 63.77% in 2022, then plummeted by -50bps to 31.98% in 2023, then grew by 9bps to 34.78% in 2024, then soared by 78bps to 61.84% in 2025.
  • Its EBIT Margin stands at 61.84% for Q3 2025, versus 53.17% for Q2 2025 and 70.75% for Q1 2025.